Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy

被引:0
|
作者
Claudio Borghi
Pathiyil Balagopalan Jayagopal
Alexandra Konradi
Luiz Aparecido Bortolotto
Luca Degli Esposti
Valentina Perrone
Jacques R. Snyman
机构
[1] University of Bologna,
[2] IRCCS Ospedale S. Orsola,undefined
[3] Lakshmi Hospital,undefined
[4] Almazov National Medical Research Center,undefined
[5] Instituto do Coração,undefined
[6] Hospital das Clinicas-FMUSP,undefined
[7] CliCon S.r.l,undefined
[8] Società Benefit-Health,undefined
[9] Economics and Outcomes Research,undefined
[10] Forte Research (Pty Ltd) and Private Practice,undefined
关键词
Hypertension; Adherence; Perindopril; Indapamide; Amlodipine; Triple single-pill combination therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Medication adherence is defined by the World Health Organization as the “extent to which a person’s behavior (in taking medication) corresponds with agreed recommendations from a healthcare provider”. Low levels of medication adherence in hypertension have been linked with increased disease burden and with higher costs for patients. Patients with hypertension whose blood pressure is poorly controlled often need to receive more than one pill. Nevertheless, having to take many pills may result in poor adherence, i.e., patients not taking their treatment as prescribed. Combining multiple drugs into a single pill for the management of hypertension is known to improve adherence; however, limited evidence exists about the benefits of triple single-pill combinations compared with equivalent free combinations in real clinical practice. This analysis evaluated changes in adherence before and after patients switched from a three-drug therapy of perindopril/indapamide single-pill + amlodipine (PER/IND + AML) to perindopril/indapamide/amlodipine (PER/IND/AML) taken as a single pill. In this analysis, real-world data from Italian administrative databases covering around 11% of the Italian population were used. Overall, 158 patients were included. More patients were found to be adherent after switch to PER/IND/AML single pill (75.3% vs 44.3% of PER/IND + AML combination). Partially adherent and poorly adherent patients were fewer with PER/IND/AML single-pill combination (10.1% and 14.6%, respectively) compared to PER/IND + AML combination (38.0% and 17.7%, respectively). These findings indicate that switching to a simplified therapy in which all three drugs are taken in one pill may offer an opportunity for increasing the number of patients that are adherent to their medication.
引用
收藏
页码:1765 / 1772
页数:7
相关论文
共 50 条
  • [1] Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy
    Borghi, Claudio
    Jayagopal, Pathiyil Balagopalan
    Konradi, Alexandra
    Bortolotto, Luiz Aparecido
    Degli Esposti, Luca
    Perrone, Valentina
    Snyman, Jacques R.
    [J]. ADVANCES IN THERAPY, 2023, 40 (04) : 1765 - 1772
  • [2] REAL-WORLD ANALYSIS OF PHARMACOUTILIZATION AND OUTCOMES OF PATIENTS ON PERINDOPRIL/AMLODIPINE/INDAPAMIDE FREE VS SINGLE-PILL COMBINATION IN ITALY
    Borghi, Claudio
    Jayagopal, Pathiyil Balagopalan
    Konradi, Alexandra
    Aparecido Bortolotto, Luiz
    Esposti, Luca Degli
    Perrone, Valentina
    Snyman, Jacques R.
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 : E310 - E310
  • [3] A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy
    Snyman, Jacques R.
    Bortolotto, Luiz Aparecido
    Esposti, Luca Degli
    Jayagopal, Pathiyil Balagopalan
    Konradi, Alexandra O.
    Perrone, Valentina
    Borghi, Claudio
    [J]. JOURNAL OF HYPERTENSION, 2024, 42 (01) : 136 - 142
  • [4] DO TRIPLE SINGLE-PILL COMBINATIONS MAKE A DIFFERENCE IN TREATMENT ADHERENCE, OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION IN HYPERTENSION? A REAL-WORLD ANALYSIS OF PATIENTS ON PERINDOPRIL/AMLODIPINE/INDAPAMIDE IN ITALY
    Snyman, J.
    Jayagopal, Balagopalan R.
    Konradi, A.
    Bortolotto, L. A.
    Degli Esposti, L.
    Perrone, V
    Borghi, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S149 - S149
  • [5] Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension
    Tsioufis, Kostas
    Douma, Stella
    Kallistratos, Manolis S.
    Manolis, Athanasios J.
    [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (04) : 385 - 393
  • [6] SINGLE-PILL TRIPLE COMBINATION OF PERINDOPRIL/INDAPAMIDE/AMLODIPINE IN PATIENTS WITH ESSENTIAL HYPERTENSION: SERBIAN EXPERIENCE
    Tasic, Nebojsa
    Tasic, Danijela
    Balevic, Milijana
    Dragisic, Dalibor
    [J]. JOURNAL OF HYPERTENSION, 2016, 34 : E445 - E445
  • [7] Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy
    de Isla, Leopoldo Perez
    Liberopoulos, Evangelos
    Dovizio, Melania
    Veronesi, Chiara
    Degli Esposti, Luca
    Zambon, Alberto
    [J]. ADVANCES IN THERAPY, 2024, 41 (08) : 3407 - 3418
  • [8] Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension
    Kostas Tsioufis
    Stella Douma
    Manolis S. Kallistratos
    Athanasios J. Manolis
    [J]. Clinical Drug Investigation, 2019, 39 : 385 - 393
  • [9] REAL-WORLD ANALYSIS OF ADHERENCE, OUTCOMES AND HEALTHCARE COSTS OF THE QUADRUPLE COMBINATION PERINDOPRIL, INDAPAMIDE, AMLODIPINE AND BISOPROLOL IN ITALY
    Mancia, Giuseppe
    Brouwers, Sofie
    Desideri, Giovambattista
    Esposti, Luca Degli
    Perrone, Valentina
    Narkiewicz, Krzysztof
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 : E483 - E483
  • [10] Efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in essential hypertension
    Wang, J.
    Bricout, S.
    Zhu, H.
    Li, X.
    Zhang, X.
    Sun, Y.
    Zhao, X.
    Li, Z.
    Zhao, R.
    Sun, Y.
    Yao, Z.
    Li, H.
    Lu, W.
    Jiang, Y.
    Han, Q.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44